Wyeth Prevenar Approval Expected By End of February
Executive Summary
Wyeth-Ayerst is expecting approval of its pneumococcal conjugate vaccine Prevenar by the end of February.
You may also be interested in...
Wyeth Protonix I.V. Indicated As Second-Line Therapy After Oral Pantoprazole
Wyeth-Ayerst's intravenous proton pump inhibitor Protonix will be launched in mid-April as a second-line alternative to Protonix (pantoprazole) tablets.
Wyeth Protonix I.V. Indicated As Second-Line Therapy After Oral Pantoprazole
Wyeth-Ayerst's intravenous proton pump inhibitor Protonix will be launched in mid-April as a second-line alternative to Protonix (pantoprazole) tablets.
EMEA Clears Four Biologics In 1999 Before FDA, And Five Later Than FDA
The European Medicines Evaluation Agency approved four biological products in 1999 that have not yet been licensed by FDA.